OKYO PHARMA LTD (OKYO:NASDAQ)
$1.51 -0.07 (-4.4304%)
Analysed OKYO PHARMA LTD (OKYO:NASDAQ) News Sources
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026
07-04-2026
proactiveinvestors.com
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
07-04-2026
yahoo.com
OKYO Pharma Announces Chairman and Founder Acquires Shares
19-03-2026
yahoo.com
OKYO Pharma Announces Director Acquires Shares
19-03-2026
yahoo.com
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
19-03-2026
yahoo.com
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
18-03-2026
proactiveinvestors.com
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
18-03-2026
yahoo.com
Dow Jones sheds more than 800 points on Trump's latest tariff threat
23-02-2026
proactiveinvestors.com
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
23-02-2026
proactiveinvestors.com
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
23-02-2026
yahoo.com
What is the current price of OKYO PHARMA LTD (OKYO:NASDAQ)?
The current price of OKYO PHARMA LTD (OKYO:NASDAQ) is $1.51.
OKYO PHARMA LTD (OKYO:NASDAQ) absolute price change since previous trading day?
The absolute price change of OKYO PHARMA LTD (OKYO:NASDAQ) since the previous trading day is $-0.07.
OKYO PHARMA LTD (OKYO:NASDAQ) percentage price change since previous trading day?
The percentage price change of OKYO PHARMA LTD (OKYO:NASDAQ) since the previous trading day is -4.4304%.
What is the most recent average sentiment score for OKYO PHARMA LTD (OKYO:NASDAQ)?
The most recent average sentiment score for OKYO PHARMA LTD (OKYO:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for OKYO PHARMA LTD (OKYO:NASDAQ)?
The most recent sentiment for OKYO PHARMA LTD (OKYO:NASDAQ) is .
SEC-8K** Filing Available For OKYO PHARMA LTD (OKYO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.